3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Multiple Myeloma
5
Recurrence
3
Lymphoma
3
Glioblastoma
3
Neoplasms
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, B-Cell, Marginal Zone
2
Glioma
2
Brain Neoplasms
2
Pancreatic Neoplasms
1
Neoplasms, Plasma Cell
1
Melanoma
1
Leukemia
1
Gliosarcoma
1
Ependymoma
1
Disease Progression
1
Diffuse Intrinsic Pontine Glioma
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Temozolomide
15
Radiotherapy
11
Everolimus
6
Bevacizumab
6
Irinotecan
5
Cyclophosphamide
5
ribociclib
4
Radiation
4
Panobinostat
4
TIC10 compound
3
Specimen Handling
3
Re-Irradiation
3
Etoposide
3
Dasatinib
3
pembrolizumab
2
nimotuzumab
2
abemaciclib
2
Vorinostat
2
Valproic Acid
2
Topotecan
2
Nivolumab
2
Mebendazole
2
Magnetic Resonance Spectroscopy
2
Granulocyte-Macrophage Colony-Stimulating Factor
2
Gemcitabine
2
GDC-0084
2
Erlotinib Hydrochloride
2
Diphtheria-Tetanus Vaccine
2
Cilengitide
2
Cetuximab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Diffuse Intrinsic Pontine Glioma
×
marizomib
×
Clear all
NCT04341311
2024-02-15
DIPG
Dana-Farber Cancer Institute
Phase 1
Terminated
4 enrolled